Merck and AstraZeneca’s Cancer Drug Wins 3 New Approvals in Japan

1 min read

On Monday, two big pharmaceutical companies delivered some good news about one of their projects. Merck (NYSE: MRK) and AstraZeneca (NASDAQ: AZN) announced in separate press releases that their cancer drug Lynparza received approval by Japan’s pharmaceutical regulator for the treatment of three types of the disease: prostate, ovarian, and pancreatic.

The country’s Ministry of Health, Labor, and Welfare approved Lynparza as a maintenance treatment following the administration of first-line chemotherapy in patients with certain types of those cancers.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Why Moderna Stock Dove by Nearly 10% on Monday

Next Story

Average Life Expectancies Are Up. Here’s How That Could Affect Your Retirement

Latest from Blog